INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NASDAQ: ADMP) investors concerning the Company’s possible violations of federal securities laws.

On May 24, 2021, Adamis disclosed that "[o]n May 11, 2021, each of the Company and its US Compounding Inc. subsidiary received a grand jury subpoena from the U.S. Attorney's Office for the Southern District of New York issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the Company's USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the Company and USC."

On this news, the Company’s stock price fell $0.0699, or over 9%, to close at $0.6740 per share on May 25, 2021.

If you purchased Adamis common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], toll-free at [phone], or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.